NurExone Biologic , a biotech company developing exosome-based therapies for central nervous system injuries, announced that it has been accepted into the HealthTech Hub Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies, HTH is operated by the Advanced Regenerative Manufacturing Institute and its BioFabUSA initiative.

Health Technology Insights: Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ

NurExone’s acceptance into the prestigious HTH Accelerator Program will support the Company’s expansion into the U.S. market following the establishment of Exo-top Inc, the Company’s wholly owned U.S. subsidiary dedicated to GMP-compliant exosome manufacturing for clinical development and commercial scale-up.

HTH, co-led by ARMI and Mass General Brigham, is a competitive accelerator program supported by the U.S. Department of Health and Human Services and Israel’s Ministry of Health. The HTH Accelerator Program selects a limited number of innovative companies each year to help them validate U.S. clinical relevance, strengthen commercialization strategies, and build meaningful collaborations with key stakeholders across the U.S. HealthTech landscape. The program is funded by HTH at no cost to participants.

Dr. Lior Shaltiel, CEO of NurExone, commented: “The HTH Acceleration Program offers the kind of U.S.-based insight and guidance needed at this stage of our growth. As we establish Exo-TOP to manufacture clinical-grade exosomes in the U.S., the HTH will help us sharpen our regulatory and scale-up strategies and pursue meaningful commercial collaboration opportunities. This is a timely and strategic opportunity to accelerate our commercialization pathway in the world’s largest healthcare market.

NurExone’s participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and to support its mission to bring novel exosome-based therapeutics to patients with unmet needs.

Health Technology Insights: Bioness Medical Announces Acquisition of the Assets and Business of Harmonic Bionics

Omnibus Plan Approval  

The Company is pleased to announce that, further to its press release dated June 4, 2025, at the Company’s annual general and special meeting held on June 18, 2025 , disinterested shareholders ratified and approved the amended and restated omnibus incentive plan, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca.

The Omnibus Plan is a hybrid plan that provides flexibility to grant-equity incentive awards in the form of stock options, restricted shares and restricted share units.

The Omnibus Plan is a hybrid 10% rolling and 10% fixed share-based compensation plan that amends and restates the Company’s previous equity incentive plan approved by shareholders on June 4, 2024. The Previous Plan was a 20% fixed share-based compensation plan whereby the maximum number of common shares in the capital of the Company reserved for issuance was set at 13,166,085, representing 20% of the issued and outstanding Common Shares as of the effective date.

The Omnibus Plan now includes (i) a 10% “rolling” Option component that shall not exceed 10% of the Company’s total issued and outstanding Common Shares from time to time; and (ii) a 10% fixed component permitting up to 7,800,781 RSUs and Restricted Shares in the aggregate.

Additionally, the Omnibus Plan was amended to increase the number of securities issuable to insiders of the Company. The Previous Plan provided, that unless approved by disinterested shareholders, (i) the maximum number of securities issuable to insiders collectively would not exceed 10% of the Company’s securities at any time and (ii) the maximum number of securities issuable to insiders collectively in any twelve-month period would not exceed 10% of the Company’s total issued and outstanding securities as at the date any award was granted to an insider. Now, the Omnibus Plan provides the following that (i) the maximum number of the Company’s securities issuable to insiders collectively shall not exceed 20% of the Company’s total issued and outstanding Common Shares at any point in time and (ii) the maximum number of the Company’s securities issuable to insiders collectively, in any 12-month period, when combined with all of the Company’s other share compensation arrangements, shall not exceed 20% of the Company’s total issued and outstanding securities, calculated as at the date any award is granted or issued to any insider.

RSU Grants

In addition, the Company announced that it has granted an aggregate of 1,125,000 RSUs to certain officers and directors of the Company pursuant to the terms and conditions of the Omnibus Plan. Each RSU vests on the one-year anniversary of the grant date and may be settled, upon their vesting, into one Common Share. 

Health Technology Insights: HRT Club, Posterity Health Partner for Inclusive Hormone Care

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – GlobalNewswire